Repurposed Acarbose Targets Nidogen-1 to Remodel the Tumor Stroma and Suppress Portal Vein Tumor Thrombus in Hepatocellular Carcinoma
Authors:
Open Access
- 1 January 2026
- journal article
- Published by American Association for the Advancement of Science (AAAS) in Research
- Vol. 9
Abstract
Portal vein tumor thrombus (PVTT) is among the most lethal complications of hepatocellular carcinoma (HCC), yet its molecular mechanisms and immune features remain poorly characterized. To address this gap, we performed a comprehensive multi-omics analysis of 99 specimens from 47 patients, integrating nCounter profiling, single-cell RNA sequencing, digital spatial profiling, and proteomics to construct the first spatial map of the PVTT microenvironment. These analyses revealed marked intratumoral heterogeneity and enrichment of myofibroblast-like cancer-associated fibroblasts (myCAFs) arising through a macrophage-to-myofibroblast transition. Nidogen-1 (NID1) was identified as a stromal driver of immune barriers, highly expressed in PVTT cores and associated with impaired antitumor immunity. Guided by these mechanistic insights, we repurposed acarbose, a Food and Drug Administration-approved drug, to inhibit the NID1 axis. Functional assays demonstrated that acarbose disrupted myCAF-mediated immune barriers, suppressed PVTT progression, and synergized with anti-programmed death-1 (anti-PD-1) therapy in preclinical models. Furthermore, analysis of an independent clinical cohort of 810 HCC patients revealed a substantially lower incidence of PVTT among those receiving acarbose, underscoring its translational potential. Collectively, these findings establish the immune–stromal landscape of PVTT, uncover NID1-driven stromal remodeling as a mechanism of immune evasion, and highlight drug repurposing as an immediately actionable strategy to improve outcomes in HCC with PVTT.Keywords
Funding Information
- National Natural Science Foundation of China (82473288)
- National Natural Science Foundation of China (82473360)
- Educational funding of Liaoning Province (LJKMZ20221135)
- Liaoning Provincial Science and Technology Plan Projects (2023020818-JH2/202)
- Shenyang supporting program for young and middle-aged technology innovation talents (RC230527)
- Shenyang Science and Technology Plan Projects (22-321-33-06)
- Liaoning Provincial Science and Technology Plan Projects (2022JH2/101300050)
- National Key Research and Development Program of China (SQ2023YFC2400004)
This publication has 58 references indexed in Scilit:
- Correction for Tang et al., Neural transcription factor Pou4f1 promotes renal fibrosis via macrophage–myofibroblast transitionProceedings of the National Academy of Sciences, 2022
- Smad3 Promotes Cancer‐Associated Fibroblasts Generation via Macrophage–Myofibroblast TransitionAdvanced Science, 2021
- Nidogen-2 Maintains the Contractile Phenotype of Vascular Smooth Muscle Cells and Prevents Neointima Formation via Bridging Jagged1-Notch3 SignalingCirculation, 2021
- Portal Vein Tumor Thrombosis and Hepatocellular Carcinoma – The Changing TidesJournal of Hepatocellular Carcinoma, 2021
- Single-cell analysis defines a pancreatic fibroblast lineage that supports anti-tumor immunityCancer Cell, 2021
- Cancer-Associated Fibroblasts Promote Vascular Invasion of Hepatocellular Carcinoma via Downregulating Decorin-integrin β1 SignalingFrontiers in Cell and Developmental Biology, 2021
- Cancer‐Associated Fibroblast‐Mediated Cellular Crosstalk Supports Hepatocellular Carcinoma ProgressionHepatology, 2021
- Nidogen 1‐Enriched Extracellular Vesicles Facilitate Extrahepatic Metastasis of Liver Cancer by Activating Pulmonary Fibroblasts to Secrete Tumor Necrosis Factor Receptor 1Advanced Science, 2020
- Management of patients with hepatocellular carcinoma and portal vein tumour thrombosis: comparing east and westThe Lancet Gastroenterology & Hepatology, 2019
- The strategies for treating primary hepatocellular carcinoma with portal vein tumor thrombusInternational Journal of Surgery, 2015